#NewMemberAseBio | "AseBio is the collective voice of the biotechnology sector"

AseBio. What does your company's work bring to the table and what is its strength?

Manuel Sánchez-Lagarejo. At Bexen Bioservices, we specialize in developing management and preservation services for temperature-sensitive samples and medications. We also strive to create innovative solutions for the preservation and development of advanced therapies.

Through our personalized, adapted, flexible, and demanding service, we apply our expertise to professionalize sample management, considering any new advancements that we can incorporate. We believe that the future of healthcare relies on advanced therapies, and therefore, we are determined to contribute, within our scope, to the development of personalized treatments as the foundation of tomorrow's medicine.

With over 45 years of experience in the industry, Bexen stands out for its manufacturing of healthcare products and single-use materials for the pharmaceutical and biotechnology sectors, following GMP standards.

Over the past decade, we have made a significant investment in the biotechnology field, becoming pioneers at a national level in the comprehensive management of biological samples and medications. We provide our users with the latest technology and the strictest quality standards.

AseBio. What is AseBio for you?

Manuel Sánchez-Lagarejo. For us, ASEBIO is the collective voice of the biotechnology sector. It allows us to have representation in political decisions, regulations, and scientific policies at the national and international levels.

ASEBIO provides us with opportunities to establish contacts and collaborate with other key actors in the sector, granting access to a broad and diverse network of companies, research institutions, investors, and other relevant stakeholders. This facilitates the creation of strategic alliances, the identification of business opportunities, and the exchange of knowledge.

Another crucial aspect of ASEBIO for us is the access to updated and relevant information on industry trends, scientific advances, calls for proposals, events, and news. Additionally, the possibility to participate in specialized working groups and committees in specific areas of biotechnology is highly valuable to us.

AseBio. When did you first hear about AseBio?

Manuel Sánchez-Lagarejo. We started hearing about ASEBIO from the moment we became part of regional healthcare associations, such as the Basque Health Cluster.

AseBio. What do you expect from being part of an association like AseBio?

Manuel Sánchez-Lagarejo. Keep developing relationships between companies in the sector in order to collectively build a strong national biotech industry, while contributing our knowledge to improve the ways in which biological samples are preserved and managed.

AseBio. What is the biggest challenge facing the biotech sector (or your company)?

Manuel Sánchez-Lagarejo. The greatest challenge of the biotech sector lies in successfully translating scientific and technological advancements into commercially viable products and therapies that have a significant impact on human health. Although biotechnology has made significant progress in areas such as personalized medicine, genetic engineering, gene therapy, and synthetic biology, the transition of these innovations from the laboratory to the market presents numerous challenges in regulatory, ethical, and industrial aspects.

Overcoming these challenges requires close collaboration among the scientific community, companies, regulatory bodies, healthcare systems, and other relevant stakeholders. Additionally, appropriate policies and regulatory frameworks are needed to foster innovation, investment, and successful commercialization of biotechnological advancements.

However, despite the obstacles, the biotech sector remains an inexhaustible source of promising breakthroughs in the fields of medicine and biology. Successfully overcoming these challenges can lead to a future with more effective, personalized, and transformative treatments for various diseases, ultimately improving the people’s quality of life.